Awakn Life Sciences (Awakn Life Sciences) Cash-to-Debt

: No Debt ⁽¹⁾ (As of Oct. 2023)

View and export this data going back to 2021. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Awakn Life Sciences's cash to debt ratio for the quarter that ended in Oct. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Awakn Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Oct. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Awakn Life Sciences's Cash-to-Debt or its related term are showing as below:

AWKNF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: 1.65 Max: No Debt
Current: 0.22

During the past 2 years, Awakn Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.16. And the median was 1.65.

AWKNF's Cash-to-Debt is ranked worse than
91.43% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs AWKNF: 0.22

Awakn Life Sciences Cash-to-Debt Historical Data

The historical data trend for Awakn Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Awakn Life Sciences Annual Data

Trend

Jan22

Jan23

Cash-to-Debt

0.90

0.24

Awakn Life Sciences Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Cash-to-Debt							0.52	0.24	0.16	No Debt	No Debt

Competitive Comparison

For the Biotechnology subindustry, Awakn Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Awakn Life Sciences Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's Cash-to-Debt falls into.

Awakn Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Awakn Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Jan. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.411	/	(0.288	+	1.422)
	=	0.24

Awakn Life Sciences's Cash to Debt Ratio for the quarter that ended in Oct. 2023 is calculated as:

Awakn Life Sciences had no debt ⁽¹⁾.

Awakn Life Sciences (OTCPK:AWKNF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Awakn Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Awakn Life Sciences (Awakn Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (OTCPK:AWKNF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

954:Germany AWKN:Canada

Address

301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2

Website

https://www.awaknlifesciences.com

Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences (Awakn Life Sciences) Headlines

From GuruFocus

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

By PRNewswire PRNewswire • 10-11-2021

CEO Presenting on the Emerging Growth Conference on June 22 Register Now

By GuruFocusNews GuruFocusNews • 07-01-2022

CEO Presenting on the Emerging Growth Conference on June 22 Register Now

By PurpleRose PurpleRose • 07-11-2022

CEO Presenting on the Emerging Growth Conference on June 22 Register Now

By GuruFocusNews GuruFocusNews • 06-21-2022